Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Teladoc, Inc. (NYSE:TDOC) by 11,741.7% during the second quarter, Holdings Channel reports. The institutional investor owned 133,338 shares of the health services provider’s stock after buying an additional 132,212 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Teladoc were worth $4,627,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the stock. Ameriprise Financial Inc. increased its stake in shares of Teladoc by 125.7% in the first quarter. Ameriprise Financial Inc. now owns 131,493 shares of the health services provider’s stock valued at $3,288,000 after buying an additional 73,231 shares in the last quarter. Driehaus Capital Management LLC purchased a new stake in shares of Teladoc during the first quarter valued at approximately $6,411,000. Blair William & Co. IL purchased a new stake in shares of Teladoc during the first quarter valued at approximately $218,000. Swiss National Bank increased its stake in shares of Teladoc by 37.5% in the first quarter. Swiss National Bank now owns 56,800 shares of the health services provider’s stock valued at $1,420,000 after buying an additional 15,500 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock valued at $6,309,000 after buying an additional 9,146 shares in the last quarter. Institutional investors own 95.88% of the company’s stock.
Teladoc, Inc. (NYSE:TDOC) opened at 31.95 on Thursday. Teladoc, Inc. has a 12 month low of $13.49 and a 12 month high of $36.90. The company has a 50-day moving average of $34.10 and a 200 day moving average of $27.41. The company’s market cap is $1.75 billion.
Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. The business had revenue of $44.60 million during the quarter, compared to analysts’ expectations of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. Teladoc’s revenue for the quarter was up 68.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.38) EPS. On average, equities analysts forecast that Teladoc, Inc. will post ($1.33) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/2797414/gilder-gagnon-howe-co-llc-increases-position-in-teladoc-inc-tdoc.html.
TDOC has been the subject of several research reports. Zacks Investment Research downgraded Teladoc from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. TheStreet upgraded Teladoc from a “d” rating to a “c-” rating in a research note on Thursday, April 13th. Piper Jaffray Companies restated a “buy” rating and issued a $42.00 target price on shares of Teladoc in a research note on Friday, July 28th. Cowen and Company raised their target price on Teladoc from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, May 31st. Finally, Robert W. Baird restated a “buy” rating and issued a $28.00 target price on shares of Teladoc in a research note on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $35.55.
In other Teladoc news, CEO Jason N. Gorevic sold 5,600 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $29.57, for a total value of $165,592.00. Following the sale, the chief executive officer now owns 823,861 shares in the company, valued at $24,361,569.77. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Mark Hirschhorn sold 100,000 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $27.70, for a total transaction of $2,770,000.00. Following the completion of the sale, the vice president now owns 80,887 shares in the company, valued at approximately $2,240,569.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 207,186 shares of company stock worth $6,122,950. Corporate insiders own 5.94% of the company’s stock.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc, Inc. (NYSE:TDOC).
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.